Alembic Pharmaceuticals' Q4 FY 2025-26 Quarterly Results

Result Summary

• Alembic Pharmaceuticals Ltd reported a 1.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 5.0%.
• Its expenses for the quarter were up by 2.7% QoQ and 8.8% YoY.
• The net profit increased 52.7% QoQ and increased 28.7% YoY.
• The earnings per share (EPS) of Alembic Pharmaceuticals Ltd stood at 10.31 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Alembic Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the manufacturing and marketing of generic pharmaceuticals. The company operates across a range of therapeutic segments, including anti-infectives, analgesics, and cardiovascular drugs, among others. Alembic Pharmaceuticals has a robust domestic presence and a growing international footprint, with a focus on expanding its product portfolio through research and development initiatives. The company continues to strengthen its market position by launching new products and forming strategic partnerships. Recent developments in the sector, such as regulatory changes and market dynamics, have the potential to impact the company’s operations, although specific recent developments for Alembic Pharmaceuticals are not available in the provided data.

Revenue

During the fourth quarter of the financial year 2026 (Q4FY26), Alembic Pharmaceuticals reported a total income of ₹1873.22 crores. This represents a slight decline of 1.0% quarter-over-quarter (QoQ) from ₹1891.81 crores in Q3FY26. However, compared to the fourth quarter of the previous financial year (Q4FY25), the company's total income increased by 5.0% from ₹1783.83 crores. The year-over-year (YoY) growth in revenue highlights a positive trajectory in the company's sales, reflecting its efforts to maintain and possibly expand its market share. Despite the QoQ decline, the YoY growth suggests that the company continues to generate higher income compared to the same period in the previous year.

Profitability

Alembic Pharmaceuticals' profitability metrics for Q4FY26 reveal notable variations. The company reported a profit before tax of ₹117.51 crores, which marks a significant decrease of 28.1% QoQ from ₹163.33 crores in Q3FY26 and a 39.0% decline YoY from ₹192.61 crores in Q4FY25. Despite this, the profit after tax for Q4FY26 increased substantially to ₹201.53 crores, representing a 52.7% QoQ rise from ₹131.95 crores in Q3FY26 and a 28.7% YoY increase from ₹156.63 crores in Q4FY25. This anomaly is primarily attributed to a negative tax expense of -₹82.91 crores in Q4FY26, compared to a positive tax expense in previous quarters. The earnings per share (EPS) for Q4FY26 stood at ₹10.31, indicating a 52.5% QoQ rise from ₹6.76 and a 29.2% YoY increase from ₹7.98, reflecting enhanced shareholder value during this period.

Operating Metrics

The total expenses for Alembic Pharmaceuticals in Q4FY26 amounted to ₹1730.95 crores, showing an increase of 2.7% QoQ from ₹1686.25 crores and an 8.8% YoY rise from ₹1591.22 crores in Q4FY25. This increase in expenses may reflect the company's operational activities, including potential investments in production, marketing, or research and development. Despite the rise in expenses, the significant increase in profit after tax suggests that the company has managed to achieve efficient cost management or other financial adjustments that bolstered its net profitability. The financial data provided does not include specific details on financial ratios or liquidity metrics such as the P/E ratio, debt-to-equity ratio, or current ratio, and as such, these cannot be calculated or analyzed within this report.